BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: de Leuw P, Stephan C. Protease inhibitor therapy for hepatitis C virus-infection. Expert Opin Pharmacother 2018;19:577-87. [PMID: 29595065 DOI: 10.1080/14656566.2018.1454428] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Prasad HSN, Ananda A, Lohith T, Prabhuprasad P, Jayanth H, Krishnamurthy N, Sridhar M, Mallesha L, Mallu P. Design, synthesis, molecular docking and DFT computational insight on the structure of Piperazine sulfynol derivatives as a new antibacterial contender against superbugs MRSA. Journal of Molecular Structure 2022;1247:131333. [DOI: 10.1016/j.molstruc.2021.131333] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Akaberi D, Chinthakindi PK, Båhlström A, Palanisamy N, Sandström A, Lundkvist Å, Lennerstrand J. Identification of a C2-symmetric diol based human immunodeficiency virus protease inhibitor targeting Zika virus NS2B-NS3 protease. J Biomol Struct Dyn 2020;38:5526-36. [PMID: 31880199 DOI: 10.1080/07391102.2019.1704882] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Foight GW, Wang Z, Wei CT, Jr Greisen P, Warner KM, Cunningham-Bryant D, Park K, Brunette TJ, Sheffler W, Baker D, Maly DJ. Multi-input chemical control of protein dimerization for programming graded cellular responses. Nat Biotechnol 2019;37:1209-16. [PMID: 31501561 DOI: 10.1038/s41587-019-0242-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
4 Aldunate F, Echeverría N, Chiodi D, López P, Sánchez-Cicerón A, Fajardo A, Soñora M, Cristina J, Hernández N, Moreno P. Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients. Dis Markers 2018;2018:2514901. [PMID: 30186532 DOI: 10.1155/2018/2514901] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
5 Andrade E, Rocha D, Fontana-Maurell M, Costa E, Ribeiro M, Godoy DT, Ferreira AGP, Tanuri A, Brindeiro R, Alvarez P. Resistance mutations of NS3 and NS5b in treatment-naïve patients infected with hepatitis C virus in Santa Catarina and Rio Grande do Sul states, Brazil. Genet Mol Biol 2020;43:e20180237. [PMID: 31644681 DOI: 10.1590/1678-4685-GMB-2018-0237] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Flick AC, Leverett CA, Ding HX, Mcinturff E, Fink SJ, Helal CJ, O’donnell CJ. Synthetic Approaches to the New Drugs Approved During 2017. J Med Chem 2019;62:7340-82. [DOI: 10.1021/acs.jmedchem.9b00196] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 7.7] [Reference Citation Analysis]
7 Akaberi D, Båhlström A, Chinthakindi PK, Nyman T, Sandström A, Järhult JD, Palanisamy N, Lundkvist Å, Lennerstrand J. Targeting the NS2B-NS3 protease of tick-borne encephalitis virus with pan-flaviviral protease inhibitors. Antiviral Res 2021;190:105074. [PMID: 33872674 DOI: 10.1016/j.antiviral.2021.105074] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Souto XM, Ramos LS, Oliveira SSC, Branquinha MH, Santos ALS. The serine peptidase inhibitor N-ρ-tosyl-l-phenylalanine chloromethyl ketone (TPCK) affects the cell biology of Candida haemulonii species complex. Fungal Biol 2021;125:378-88. [PMID: 33910679 DOI: 10.1016/j.funbio.2020.12.004] [Reference Citation Analysis]
9 Delshadi R, Bahrami A, McClements DJ, Moore MD, Williams L. Development of nanoparticle-delivery systems for antiviral agents: A review. J Control Release 2021;331:30-44. [PMID: 33450319 DOI: 10.1016/j.jconrel.2021.01.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
10 Houghton M. Hepatitis C Virus: 30 Years after Its Discovery. Cold Spring Harb Perspect Med. 2019;9. [PMID: 31501269 DOI: 10.1101/cshperspect.a037069] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Meng S, Tang GL, Pan HX. Enzymatic Formation of Oxygen-Containing Heterocycles in Natural Product Biosynthesis. Chembiochem 2018;19:2002-22. [PMID: 30039582 DOI: 10.1002/cbic.201800225] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
12 Jiang X, Yu J, Zhou Z, Kongsted J, Song Y, Pannecouque C, De Clercq E, Kang D, Poongavanam V, Liu X, Zhan P. Molecular design opportunities presented by solvent‐exposed regions of target proteins. Med Res Rev 2019;39:2194-238. [DOI: 10.1002/med.21581] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
13 Gaglia MM, Munger K. More than just oncogenes: mechanisms of tumorigenesis by human viruses. Curr Opin Virol 2018;32:48-59. [PMID: 30268926 DOI: 10.1016/j.coviro.2018.09.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
14 Liu W, Caglar MU, Mao Z, Woodman A, Arnold JJ, Wilke CO, Cameron CE. More than efficacy revealed by single-cell analysis of antiviral therapeutics. Sci Adv 2019;5:eaax4761. [PMID: 31692968 DOI: 10.1126/sciadv.aax4761] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
15 Luna JM, Saeed M, Rice CM. Taming a beast: lessons from the domestication of hepatitis C virus. Curr Opin Virol 2019;35:27-34. [PMID: 30875640 DOI: 10.1016/j.coviro.2019.02.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
16 Van Lam van T, Ivanova T, Hardes K, Heindl MR, Morty RE, Böttcher-Friebertshäuser E, Lindberg I, Than ME, Dahms SO, Steinmetzer T. Design, Synthesis, and Characterization of Macrocyclic Inhibitors of the Proprotein Convertase Furin. ChemMedChem 2019;14:673-85. [PMID: 30680958 DOI: 10.1002/cmdc.201800807] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
17 Cuypers L, Thijssen M, Shakibzadeh A, Deboutte W, Sarvari J, Sabahi F, Ravanshad M, Pourkarim MR. Signature of natural resistance in NS3 protease revealed by deep sequencing of HCV strains circulating in Iran. Infect Genet Evol 2019;75:103966. [PMID: 31323326 DOI: 10.1016/j.meegid.2019.103966] [Reference Citation Analysis]
18 Fischer A, Sellner M, Neranjan S, Smieško M, Lill MA. Potential Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 606 Million Compounds. Int J Mol Sci 2020;21:E3626. [PMID: 32455534 DOI: 10.3390/ijms21103626] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 29.0] [Reference Citation Analysis]
19 Kammarabutr J, Mahalapbutr P, Nutho B, Kungwan N, Rungrotmongkol T. Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation. J Mol Graph Model 2019;89:122-30. [PMID: 30884449 DOI: 10.1016/j.jmgm.2019.03.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
20 Ceccherini-Silberstein F, Cento V, Di Maio VC, Perno CF, Craxì A. Viral resistance in HCV infection. Curr Opin Virol 2018;32:115-27. [PMID: 30439589 DOI: 10.1016/j.coviro.2018.10.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
21 Voss S, Nitsche C. Inhibitors of the Zika virus protease NS2B-NS3. Bioorg Med Chem Lett 2020;30:126965. [PMID: 31980339 DOI: 10.1016/j.bmcl.2020.126965] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
22 Koutsoumpli G, Ip PP, Schepel I, Hoogeboom BN, Boerma A, Daemen T. Alphavirus-based hepatitis C virus therapeutic vaccines: can universal helper epitopes enhance HCV-specific cytotoxic T lymphocyte responses? Ther Adv Vaccines Immunother 2019;7:2515135519874677. [PMID: 31620673 DOI: 10.1177/2515135519874677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Hu K, Zhu Z, Mathahs MM, Tran H, Bommer J, Testa CA, Schmidt WN. Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure-Activity Relationships. Drug Des Devel Ther 2020;14:757-71. [PMID: 32158194 DOI: 10.2147/DDDT.S201089] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Qin W, Zhao B, Shang Y, Zhang L. Clinical profile of acute pancreatitis following treatment with protease inhibitors: a real-world analysis of post-marketing surveillance data. Expert Opin Drug Saf 2021;20:1109-15. [PMID: 34018864 DOI: 10.1080/14740338.2021.1933942] [Reference Citation Analysis]
25 Bernatchez JA, Tran LT, Li J, Luan Y, Siqueira-Neto JL, Li R. Drugs for the Treatment of Zika Virus Infection. J Med Chem 2020;63:470-89. [PMID: 31549836 DOI: 10.1021/acs.jmedchem.9b00775] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
26 Voss S, Nitsche C. Targeting the protease of West Nile virus. RSC Med Chem 2021;12:1262-72. [PMID: 34458734 DOI: 10.1039/d1md00080b] [Reference Citation Analysis]